SCDM Updated CCDM Exam Questions and Answers by avani

If a clinical site continues to provideinconsistent or illogical dataafter multiple queries, the correct course of action is toescalate the issue to the appropriate site contact personnel, typically theClinical Research Associate (CRA)orSite Monitor.

According to theGood Clinical Data Management Practices (GCDMP), persistent data discrepancies often indicate a misunderstanding of the protocol, CRF instructions, or data entry procedures at the site level. Repeatedly re-querying the same data without escalation wastes time and risks introducing bias or error. By escalating through formal communication channels, the issue can be clarified through re-training, documentation review, or site monitoring visits.

The GCDMP emphasizes that escalation ensuresdata accuracy, site accountability, and protocol adherence, maintaining both data quality and regulatory compliance. Data managers must document the escalation process in the Data Management Plan (DMP) and ensure proper follow-up resolution is achieved.

Reference (CCDM-Verified Sources):

SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Communication and Issue Escalation, Section 4.2 – Handling Persistent Data Discrepancies

ICH E6 (R2) Good Clinical Practice, Section 5.18 – Monitoring and Site Communication

FDA Guidance for Industry: Oversight of Clinical Investigations – Risk-Based Monitoring, Section on Issue Escalation

Whenlaboratory dataare missing from a paper-based clinical study, theData Managershould directdata-entry personnel to issue a queryto the investigative site for clarification or correction.

According to theGood Clinical Data Management Practices (GCDMP, Chapter: Data Validation and Cleaning), every missing, inconsistent, or out-of-range data point must be reviewed and, if necessary, resolved through the formalquery management process. This ensures that all discrepancies between the source documents and database entries are properly documented, traceable, and auditable.

Data-entry staff arenot authorizedto infer or fill in missing information. They must escalate such discrepancies to the site via query, preservingdata integrityandregulatory compliancewithICH E6 (R2)andFDA 21 CFR Part 11. Calling the patient directly (option B) would violate confidentiality and site communication protocol, while simply flagging or ignoring the issue (options A and D) would not meet GCDMP query resolution standards.

Reference (CCDM-Verified Sources):

SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Data Validation and Cleaning, Section 5.2 – Query Management and Resolution

ICH E6 (R2) Good Clinical Practice, Section 5.18.4 – Communication of Data Discrepancies

FDA 21 CFR Part 11 – Electronic Records; Query Audit Trails Requirements

This scenario describes asingle-blindtrial, in whichonly one party—typically thesubject—is unaware of the treatment assignment, while theinvestigator or surgeonknows which intervention is being administered.

In this case, thesurgeonreceives instructions on which stent (test or control) to use, meaning they are aware of treatment allocation. However, thesubject is blindedto which device is being implanted. This setup minimizes subject bias while maintaining procedural safety since the surgeon must know which product to use.

Double-blind (A):Neither subject nor investigator knows the treatment.

Open-label (B):Both subject and investigator know the treatment.

Cross-over (D):Each subject receives both treatments in different periods.

Thus, the correct answer isC. Single-blind, as only the participant remains blinded in this surgical device trial design.

Reference (CCDM-Verified Sources):

SCDM GCDMP, Chapter: Clinical Trial Phases and Protocols, Section 3.2 – Study Blinding and Randomization Concepts

ICH E6(R2) GCP, Section 1.10 – Definition of Blinding/Masking

FDA Guidance for Industry: Design Considerations for Pivotal Clinical Investigations for Medical Devices, Section 5.3 – Blinding in Device Studies

Themost common mode of data entryinElectronic Data Capture (EDC)systems issingle data entry.

According to theGCDMP (Chapter: Electronic Data Capture Systems), EDC systems have built-inedit checks, validation rules, and audit trailsthat ensure data accuracy and integrity at the point of entry. These real-time validation capabilities makedouble data entry(a legacy practice from paper studies) unnecessary.

EDC systems automatically verify data as they are entered by site staff, generating queries for inconsistencies or out-of-range values immediately.Blind verification (option B)andthird-party comparisons (option D)are not standard data entry modes but may be used for specialized reconciliation or external data imports.

Thus,single data entry (Option C)is the industry standard approach, ensuring both efficiency and compliance withFDA 21 CFR Part 11andICH E6 (R2)data integrity requirements.

Reference (CCDM-Verified Sources):

SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Electronic Data Capture (EDC) Systems, Section 5.4 – Data Entry and Verification Processes

ICH E6 (R2) Good Clinical Practice, Section 5.5.3 – Computerized Systems and Data Validation

FDA 21 CFR Part 11 – Electronic Records and Electronic Signatures: Validation and Data Entry Requirements